The utility of a multidomain assessment of steroid response for predicting clinical response to omalizumab

J Allergy Clin Immunol. 2016 Jul;138(1):292-294. doi: 10.1016/j.jaci.2015.12.1317. Epub 2016 Feb 28.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adrenergic beta-Agonists / therapeutic use
  • Anti-Asthmatic Agents / therapeutic use*
  • Asthma / diagnosis*
  • Asthma / drug therapy*
  • Asthma / immunology
  • Asthma / physiopathology
  • Biomarkers / analysis
  • Child
  • Female
  • Humans
  • Ipratropium / therapeutic use
  • Leukotriene Antagonists / therapeutic use
  • Male
  • Nitric Oxide / analysis
  • Omalizumab / therapeutic use*
  • Prognosis
  • Spirometry
  • Sputum / chemistry
  • Triamcinolone / therapeutic use*
  • Vital Capacity

Substances

  • Adrenergic beta-Agonists
  • Anti-Asthmatic Agents
  • Biomarkers
  • Leukotriene Antagonists
  • Triamcinolone
  • Omalizumab
  • Nitric Oxide
  • Ipratropium